PubRank

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Clinical Trial ID NCT02027961

PubWeight™ 17.96‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02027961

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
2 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
3 Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014 1.33
4 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
5 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
6 BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015 0.99
7 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
8 Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014 0.95
9 Updates in Therapy for Advanced Melanoma. Cancers (Basel) 2016 0.91
10 Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 2015 0.82
11 Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015 0.82
12 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
13 The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget 2016 0.79
14 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
15 Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol 2016 0.78
16 New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014 0.77
17 Intellectual property issues of immune checkpoint inhibitors. MAbs 2015 0.75
18 CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res 2015 0.75
19 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
Next 100